Understanding a Rebalancing Therapy Option for Hemophilia

Join us for an educational session exploring a rebalancing treatment option for hemophilia.

You’ll hear:

• The science behind rebalancing therapy

• Clinical trial data

• Safety information

• Information on administration

• Shared decision-making tips for patients and caregivers

Join us for an educational session exploring a rebalancing treatment option for hemophilia.

Speaker: Brad Schoenfeld, Director of Advocacy and Community Engagement, Pfizer

Brad serves as advocacy and community engagement team lead within Pfizer's U.S. Rare Disease Patient Affairs unit. Prior to joining Pfizer in 2020, he served as President, New York City Hemophilia Chapter (NYCHC). In 2017, he received the Award of Distinction presented at its annual Gala. In 2013, Brad was the recipient of the Award of Excellence by the National Hemophilia Foundation (now National Bleeding Disorders Foundation).

Of note, in 2010, Brad formulated the marketing strategy, creative directed the poster design, served as publicist and helped to form a distribution collaboration with Gay Men’s Health Crisis (now GMHC) and PBS, all in support of the documentary feature “Bad Blood: A Cautionary Tale.”